

# Satrix Healthcare Innovation Feeder ETF

## Initial Public Offering

The **Satrix Healthcare Innovation Feeder exchange traded fund** (ETF) seeks to track the performance of the STOXX Global Breakthrough Healthcare index, which is composed of developed and emerging market companies that generate significant revenues from specific sectors focused on pushing the boundaries in medical treatment and technology.

This global ETF will list on the Johannesburg Stock Exchange (JSE) and investors will access it in South African Rand. Satrix will replicate the index by investing in the **iShares Healthcare Innovation UCITS ETF**.

### INITIAL PUBLIC OFFERING (IPO)

By participating in this IPO, you will have the benefit of investing in this ETF at listing price and pay zero brokerage and trading fees, and no buy-sell (bid-offer) spread applies.

|                     |                               |
|---------------------|-------------------------------|
| IPO opens           | 09:00am, 4 May 2022           |
| IPO closes          | 12:00pm (midday), 17 May 2022 |
| JSE listing date    | 26 May 2022                   |
| JSE listing code    | STXHLT                        |
| Targeted annual TER | 0.60%                         |
| Risk profile        | Aggressive                    |

### ABOUT THE INDEX

The **STOXX Global Breakthrough Healthcare index** is comprised of companies from selected countries that are exposed to a defined theme, namely Healthcare Innovation. These companies, or significant components of their business lines, are positioned to benefit from long-term structural trends such as shifting global demographics, social changes and the increased application of technology.

The index invests in companies involved in researching, developing, and manufacturing new drugs, medical devices and/or services for the healthcare industry. In addition, the index excludes companies which do not meet minimum ESG requirements.

### INDEX TOP 10 CONSTITUENTS


| COMPANY                       | INDEX WEIGHT | SUB CATERGORY                 | COUNTRY |
|-------------------------------|--------------|-------------------------------|---------|
| ABBVIE                        | 1,61%        | Biotechnology                 | USA     |
| DEXCOM                        | 1,48%        | Healthcare Equipment          | USA     |
| Thermo Fisher Scientific Inc. | 1,46%        | Life Sciences Tools & Service | USA     |
| Hologic Inc.                  | 1,42%        | Healthcare Equipment          | USA     |
| UCB                           | 1,39%        | Pharmaceuticals               | Belgium |
| Edwards Lifesciences Corp.    | 1,36%        | Healthcare Equipment          | USA     |
| Cerner Corp.                  | 1,33%        | Healthcare Equipment          | USA     |
| Biohaven Pharmaceutical Hhg   | 1,32%        | Biotechnology                 | USA     |
| ABIOMED                       | 1,28%        | Healthcare Equipment          | USA     |
| Bristol-Myers Squibb Co.      | 1,25%        | Pharmaceuticals               | USA     |

Source: STOXX data | 31 March 2022

## WHY CHOOSE THIS FUND


- This is a thematic fund investing across sectors and geographies in companies set to benefit from long-term global structural changes such as shifting demographics, changing economic power and technological breakthrough which should lead to above average earnings growth.
- Demographics and an ageing population, coupled with technological breakthroughs in global healthcare, mean a higher share of spending will go towards healthcare and makes for compelling investment themes.
- Healthcare spending is minimally dependent on the business cycle and offers the potential for increased diversification within portfolios.
- Technological breakthrough and innovation within the healthcare sector provides the potential for above average earnings growth where the speed of disruption and innovation is typically underestimated by the market.
- This fund offers highly diversified yet investable exposure to a broad range of companies involved in healthcare innovation globally, and is additionally screened to meet minimum environmental, social and governance (ESG) criteria.
- This ETF will track a wider healthcare exposure than other healthcare indices, thus offering better diversification and allows for a long-term view within an equity allocation.
- It is suitable for investors with a long-term view for their equity allocation.

## INDEX PERFORMANCE




Source: STOXX data | 31 March 2022

## INDEX COMPOSITION BY SECTOR



Source: BlackRock | 31 March 2022

## INDEX COMPOSITION BY COUNTRY



Source: STOXX data | 31 March 2022

## HOW TO ACCESS THIS ETF

SatrixNOW platform

Other investment platforms

JSE member stockbrokers

## FOR MORE INFORMATION: [www.satrix.co.za](http://www.satrix.co.za)

Satrix Managers (RF) (Pty) Ltd (Satrix) a registered and approved Manager in Collective Investment Schemes in Securities. Collective investment schemes are generally medium- to long-term investments. Unit Trusts and ETFs the investor essentially owns a "proportionate share" (in proportion to the participatory interest held in the fund) of the underlying investments held by the fund. With Unit Trusts, the investor holds participatory units issued by the fund while in the case of an ETF, the participatory interest, while issued by the fund, comprises a listed security traded on the stock exchange. ETFs are index tracking funds, registered as a Collective Investment and can be traded by any stockbroker on the stock exchange or via Investment Plans and online trading platforms. ETFs may incur additional costs due to it being listed on the JSE. Past performance is not necessarily a guide to future performance and the value of investments / units may go up or down. A schedule of fees and charges, and maximum commissions are available on the Minimum Disclosure Document or upon request from the Manager. Collective investments are traded at ruling prices. A feeder fund is a portfolio that invests in a single portfolio of a collective investment scheme, which levies its own charges and which could result in a higher fee structure for the feeder fund. International investments or investments in foreign securities could be accompanied by additional risks such as potential constraints on liquidity and repatriation of funds, macroeconomic risk, political risk, foreign exchange risk, tax risk, settlement risk as well as potential limitations on the availability of market information. The manager has the right to close the portfolio to new investors in order to manager it more efficiently in accordance with its mandate.